Showing 35,024 articles by Roger Pebody

Filters Author: Roger Pebody

Roger joined NAM in 2008 as an Editor and became Managing Editor in 2018. He is responsible for co-ordinating the editorial content of aidsmap.com, including news coverage and patient information materials. His involvement in HIV work began at Gay Men Fighting AIDS in the mid-1990s. Twitter: @RogerPebody

PrEP

'Thinking About Sex?' DC Uses Racy Ad to Promote Anti-HIV Drug

Editor's pick
NBC4 Washington
10 January 2018
Global health targets

London joins Fast-Track Cities initiative to reduce new HIV infections

Editor's pick
Mayor of London
10 January 2018
Government, leadership & policy

Experts worry about consequences of Trump’s HIV/AIDS council firings

Editor's pick
Healio
10 January 2018
Pharmaceutical industry

Teva Announces Exclusive Launch of a Generic Version of Reyataz® in the United States

Editor's pick
Teva press release
10 January 2018
Harm reduction

HIV spike linked to injection-drug use hits Cincinnati area

Editor's pick
USA TODAY
10 January 2018
Injectable & long-acting HIV treatment

New 'mini-pillbox' device could deliver three HIV drugs in a single once-weekly dose

News
9 January 2018
Hepatitis C treatment

India to launch national program to control viral hepatitis and aims to negotiate lower drug prices

Editor's pick
Pharma Letter
9 January 2018
PrEP

Usage remains low for pill that can prevent HIV infection

Editor's pick
ABC News
9 January 2018
Undetectable viral load & treatment as prevention

Do you speak U=U? Talking to patients about treatment as prevention

Editor's pick
BHIVA
9 January 2018
Pharmaceutical industry

Brexit: Fears of disruption to flow of medicines means UK must stay under EU regulation, say government figures

Editor's pick
The Independent
9 January 2018
Bone & joint problems

Twice the rate of bone loss among ART-treated women than men

News
9 January 2018
PrEP

Kenya: HIV prevention pill yet to catch on

Editor's pick
Daily Nation
8 January 2018
Transgender people

Trans Lives Matter

Editor's pick
Poz
8 January 2018
New & experimental HIV treatments

New long-acting, less-toxic HIV drug suppresses virus in humanized mice

Editor's pick
Yale News
8 January 2018
New & experimental HIV treatments

FDA Accepts New Drug Applications for Merck’s Doravirine, the Company’s Investigational Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), for Treatment of HIV-1 Infection

Editor's pick
Merck press release
8 January 2018
Hepatitis C treatment

England: 25,000 Hepatitis C patients receive new treatments

Editor's pick
NHS England
8 January 2018
Lung disease

High prevalence of emphysema in middle-aged HIV-positive smokers

News
8 January 2018
Economic & social inequality

Children Exposed to Drugs, Violence Experience Higher Incidence of HIV as Adults

Editor's pick
MD Mag
7 January 2018
Tuberculosis & HIV

An Inside Look At Ukraine's Terrifying TB Outbreak

Editor's pick
Worldcrunch / Suddeutsche Zeitung
7 January 2018
Finding support

Social Connectedness and HIV: Strategies for Better Health

Editor's pick
The Body
7 January 2018
Resistance

Immediate HIV Treatment Has Little Impact on Risk of Future Drug Resistance

Editor's pick
The Body Pro
7 January 2018
People & personal stories

NYC Gets Its First Openly HIV-Positive City Council Speaker

Editor's pick
Poz
7 January 2018
PrEP

New Online Resource For PrEP Created By Dublin-Based Activists

Editor's pick
Gay Community News
7 January 2018
How HIV works

Suboptimal ART adherence associated with greater inflammation in patients with HIV

Editor's pick
Healio
7 January 2018